SCHEMBL3760258

SCHEMBL3760258

Nc1cn[c]c(-c2ccccc2)c1N1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.38
HSD17B10 Q99714 3/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 2/20 0.38
USP2 O75604 1/20 0.38
KEAP1 Q14145 1/20 0.38
ALDH1A1 P00352 7/20 0.36
KDM4E B2RXH2 5/20 0.36
NPC1 O15118 4/20 0.36
RAB9A P51151 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NOS1 P29475 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HPGD P15428 4/20 0.35
MAPT P10636 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ADORA2A P29274 2/20 0.35
ADRA2A P08913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757772 0.98 HSD17B10 (0.40) HTTHSD17B10LMNATSHRUSP2
SCHEMBL3763028 0.97 LMNA (0.35) HTTHSD17B10LMNATSHRUSP2
SCHEMBL3759744 0.77 NPY5R (0.36) HTTHSD17B10LMNATSHRUSP2
SCHEMBL3765786 0.76 HPGD (0.46) HTTLMNATSHRALDH1A1KDM4E
SCHEMBL3759709 0.75 NPY5R (0.32) HSD17B10TSHRUSP2ALDH1A1KDM4E
SCHEMBL3751377 0.73 NPY5R (0.41) HTTHSD17B10LMNAKEAP1ALDH1A1
SCHEMBL3754790 0.72 NPY5R (0.43) HTTHSD17B10LMNATSHRKEAP1
SCHEMBL3759089 0.71 ADORA2A (0.39) HTTHSD17B10LMNATSHRUSP2
SCHEMBL3763849 0.70 MAPT (0.38) HTTHSD17B10LMNATSHRUSP2
SCHEMBL3756163 0.70 KDM4E (0.41) HSD17B10LMNATSHRKEAP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HTT 1234/4885HSD17B10 2922/4885LMNA 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.